BiomX
NYSE: PHGEDelaware corporation · 5 known investors
BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security. It targets field-proven products serving homeland security, critical infrastructure, border, transportation, and public safety needs within a Detection, Analysis, and Response operational chain.
Founders & leadership
JS
Jonathan SolomonChief Executive Officer
MB
Merav BassanChief Development Officer
MW
Marina WolfsonChief Financial Officer
JG
Jesse GoodmanNamed on SEC filing
AM
Alan MosesNamed on SEC filing
JL
Jonathan LeffNamed on SEC filing
GM
Gregory MerrilNamed on SEC filing
EW
Eddie WilliamsNamed on SEC filing
SB
Susan BlumNamed on SEC filing
RG
Russell GreigNamed on SEC filing
PS
Paul SekhriNamed on SEC filing
JG
Jonas GrossmanNamed on SEC filing
Investors · 5
Competitors · 3
by search overlapRobinhood20 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha19 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
TradingView16 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies competing with BiomX for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements$72.3M disclosed across 5 rounds · 2021–2026
▶$3.3MraisedJan 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedJan 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jesse GoodmanDirector
- Alan MosesDirector
- Jonathan LeffDirector
- Jonathan SolomonExecutive Officer, Director
- Merav BassanExecutive Officer
- Gregory MerrilDirector
- Eddie WilliamsDirector
- Susan BlumDirector
- Russell GreigDirector
- Marina WolfsonExecutive Officer
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- Sales commissions
- $210K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$61.5MraisedApr 2024 · 34 investors · PharmaceuticalsRule 506(b)
▶$61.5MraisedApr 2024 · 34 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jesse GoodmanDirector
- Assaf OronExecutive Officer
- Russell GreigDirector
- Edward WilliamsDirector
- Gregory MerrilDirector
- Marina WolfsonExecutive Officer
- Jonathan LeffDirector
- Jonathan SolomonExecutive Officer, Director
- Alan MosesDirector
- Avi GabayExecutive Officer
- Merav BassanExecutive Officer
- Offering amount
- $61.5M
- Amount sold
- $61.5M
- Sales commissions
- $1.4M
- Placement agents
- RBC Capital Markets, LLC, Laidlaw & Company (UK) Ltd.
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMar 2023 · 10 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedMar 2023 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Russell GreigDirector
- Lynne SullivanDirector
- Assaf OronExecutive Officer
- Merav BassanExecutive Officer
- Alan MosesDirector
- Marina WolfsonExecutive Officer
- Jonathan SolomonExecutive Officer, Director
- Offering amount
- $7.5M
- Amount sold
- $1.5M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedJan 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedJan 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonas GrossmanDirector
- Lynne SullivanDirector
- Gbola AmusaDirector
- Marina WolfsonExecutive Officer
- Russell GreigDirector
- Alan MosesDirector
- Paul SekhriDirector
- Merav BassanExecutive Officer
- Jonathan Eitan SolomonExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $3M
- Minimum investment
- $3M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$3MraisedOct 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedOct 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan Eitan SolomonExecutive Officer, Director
- Paul SekhriDirector
- Russell GreigDirector
- Jonas GrossmanDirector
- Lynne SullivanDirector
- Sailaja PuttaguntaExecutive Officer
- Marina WolfsonExecutive Officer
- Merav BassanExecutive Officer
- Alan MosesDirector
- Gbola AmusaDirector
- Offering amount
- $3M
- Amount sold
- $3M
- Minimum investment
- $3M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.